论文部分内容阅读
慢性阻塞性肺疾病(COPD)是呼吸系统疾病中的常见病和多发病,WHO预测到2020年COPD将成为全球第三大死亡原因[1]。美国胸科协会和欧洲呼吸学会2004年颁布的诊疗指南中,对中重度COPD稳定期患者建议使用吸入糖皮质激素(ICS)加吸入长效β-2受体激动剂(LABA)联合治疗[2]。杭州市萧山区第二人民医院自2010年6月~2011年6月在COPD
Chronic Obstructive Pulmonary Disease (COPD) is a common and frequently occurring disease in respiratory diseases. WHO predicts that COPD will be the third leading cause of death in the world by 2020 [1]. The American Thoracic Society and the European Respiratory Society guidelines for treatment in 2004 recommended the use of inhaled glucocorticoid (ICS) plus inhaled long-acting β-2 receptor agonist (LABA) in patients with stable-to-moderate COPD [2 ]. Xiaoshan District, Hangzhou Second People’s Hospital since June 2010 ~ June 2011 in COPD